Poolbeg Pharma PLC Key POLB 002 European Patent Granted (3407I)
April 14 2022 - 1:00AM
UK Regulatory
TIDMPOLB
RNS Number : 3407I
Poolbeg Pharma PLC
14 April 2022
Poolbeg Pharma plc
Key POLB 002 European Patent Granted
Continued expansion of the POLB 002 patent family following
European Patent Office approval
14 April 2022 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a clinical stage infectious disease
pharmaceutical company with a unique capital light clinical model,
provides an update on the strengthening of its intellectual
property (IP) for its asset POLB 002, a first-in-class,
intranasally administered RNA-based immunotherapy for respiratory
virus infections.
In January this year , Poolbeg secured an exclusive licence for
the dual antiviral prophylactic and therapeutic candidate, which is
being developed as POLB 002. Data suggests it could provide
pan-viral protection from respiratory virus infections including
influenza, respiratory syncytial virus (RSV), SARS-CoV-2 and
others. As a nasally administered and rapidly effective
prophylactic antiviral candidate, it could potentially provide an
effective solution for protecting at risk patient populations (e.g.
the elderly, COPD patients, and asthmatics).
The European Patent Office has granted this important patent in
the POLB 002 patent family, which protects the use of a defective
interfering (DI) influenza virus against infection by influenza.
POLB 002 works by triggering nasal cells into an antiviral state
using DI influenza that r esembles the infectious influenza virus
but doesn't have the ability to replicate and therefore can provoke
an appropriate immune response but does not cause an infection. The
Company will continue working with its patent advisors to broaden
and expand this patent family, including the method by which
defective interfering antiviral agents can be identified.
Discussions with patent authorities in other jurisdictions,
including the US, are continuing with further positive
announcements expected following a recent 'Notice of Allowance'
communication from the US patent authorities.
The development of POLB 002 and these patent updates come at a
critical time with a global focus on respiratory virus infections
and when such viruses are considered a top five global killer,
resulting in more than three million annual deaths worldwide. The
pandemic potential of influenza continues to be monitored closely
by the global health authorities, while the World Health
Organization (WHO) and infectious hazard experts have guided that
there is statistical certainty that a future influenza pandemic can
be expected. The CDC has advised that early action and effective
preparedness are absolutely essential to mitigating risk, hence
highlighting the importance of developing vaccines, prophylactics
and antiviral treatments against viruses; with pan-viral products
offering an important solution.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said: "The
granting of this patent marks an important step in our development
and protection of this important respiratory virus disease
treatment. Data for POLB 002 shows it is able to both prevent viral
infections and rapidly reduce viral loads where infection has
occurred, improving disease symptoms and aiding recovery. This
makes it an attractive candidate in a market where a significant
unmet need for the treatment of most respiratory virus infections
still exists.
"Our patent portfolio in Europe, US and elsewhere for POLB 002
are growing as part of our overall strategy to enhance the
protection of Poolbeg's assets and we look forward to updating
shareholders on future patent grants."
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
finnCap Ltd (Nominated Adviser & Joint
Broker)
Geoff Nash, James Thompson, Charlie
Beeson
Richard Chambers, Sunila de Silva (ECM) +44 (0) 207 220 0500
Arden Partners PLC (Joint Broker)
John Llewellyn-Lloyd, Louisa Waddell +44 (0) 207 614 5900
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Instinctif Partners +44 (0) 20 7457 2020
Melanie Toyne Sewell, Rozi Morris, Tim poolbeg@instinctif.com
Field
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease
pharmaceutical company, with a capital light clinical model which
aims to develop multiple products faster and more cost effectively
than the conventional biotech model. The Company, headquartered in
London, is led by a team with a track record of creation and
delivery of shareholder value and aspires to become a "one-stop
shop" for Big Pharma seeking mid-stage products to license or
acquire.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025.
With its initial assets from Open Orphan plc , an industry
leading infectious disease and human challenge trials business,
Poolbeg has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage
products, reducing spend and risk. Amongst its portfolio of
exciting assets, Poolbeg has a small molecule immunomodulator for
severe influenza (POLB 001); a first-in-class, intranasally
administered RNA-based immunotherapy for respiratory virus
infections (POLB 002); and a vaccine for Melioidosis (POLB 003).
The Company is also developing an oral vaccine delivery platform
and is progressing two artificial intelligence (AI) drug discovery
programmes to accelerate the power of its human challenge model
data and biobank.
For more information, please go to www.poolbegpharma.com or
follow us @PoolbegPharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFLASFIVLIF
(END) Dow Jones Newswires
April 14, 2022 02:00 ET (06:00 GMT)
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jul 2023 to Jul 2024